Skip to content

Effect of butorphanol on preventing sufentanil-induced cough in patients undergoing laparoscopic general anesthesia during induction:A multi-center, randomized, controlled, double-blind trial

Effect of butorphanol on preventing sufentanil-induced cough in patients undergoing laparoscopic general anesthesia during induction:A multi-center, randomized, controlled, double-blind trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100048774
Enrollment
Unknown
Registered
2021-07-16
Start date
2021-07-19
Completion date
Unknown
Last updated
2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse reactions related to narcotic drugs

Interventions

Normal Saline control group:Pretreatment with equal amount of normal saline
10µg/kg butorphanol experiment group:Pretreatment with 10µg/kg butorphanol
10µg/kg butorphanol experiment group:Pretreatment with 20µg/kg butorphanol

Sponsors

Hunan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years; 2. For patients undergoing elective general anesthesia abdominal laparoscopic surgery requiring postoperative analgesia pump, the estimated operation time 1-4 hours; 3. ASA score I-III; 4. 18.5kg/m2<BMI<30kg/m2; 5. Clearly understand and voluntarily participate in the research, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Opioid-tolerant patients; 2. Patients who are dependent on narcotine; 3. Pregnant and lactating women; 4. Unable to cooperate due to mental illness or other reasons; 5. Patients with central nervous system disease before surgery; 6. History of chronic pain (pain symptoms for more than 3 months); 7. Patients taking sedatives, antidepressants or drugs that excite the central nervous system before surgery; 8. Alcoholism; 9. Patients with bronchial asthma or chronic obstructive pulmonary disease before surgery; 10. Patients who have taken steroids and bronchodilators in the past two weeks; 11. Patients with upper respiratory tract infection in the past two weeks 12. Past history of PONV or motion sickness 13. Patients with myocardial infarction, ventricular dysfunction, and coronary insufficiency; 14. Participate in other drug clinical investigators within the past three months.

Design outcomes

Primary

MeasureTime frame
Incidence of cough;

Secondary

MeasureTime frame
Severity of cough occurrence;Vital signs;Intraoperative blood loss;Blood transfusion Volume;Rehydration fluids;??;Wake-up quality;Ramsay sedation score;Agitation score;Postoperative nausea and vomiting score;VAS score;Adverse reactions;

Countries

China

Contacts

Public ContactKong Gaoyin

Hunan Provincial People's Hospital

konggaoyin@sina.com+86 13908476981

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026